Skip to main content

2020 HMS I-Hub and HMS Translator Symposium

October 28th, 2020 ~ 01:00pm–03:30pm
Zoom; please register for details

Harvard Medical School hosts this virtual symposium to celebrate the launch of the HMS Ideation Hub (I-Hub) and HMS Translator.

Register Here

The symposium will feature a special discussion about emerging techniques, the future of medicine, and the direction of the industry as well as presentations by (in order of appearance):

George Q. Daley, MD, PhD
Dean of the Faculty of Medicine, Harvard University
Caroline Shields Walker Professor of Medicine, Harvard Medical School
 
Tim Mitchison, PhD
Director of the I-Hub, Harvard Medical School
Hasib Sabbagh Professor of Systems Biology, Harvard Medical School
 
Ifat Rubin-Bejerano, PhD
Director of Translational Research Programs, Harvard Medical School
 
Mark Namchuk, PhD
Executive Director of Therapeutics Translation, Harvard Medical School
 
Len Blavatnik, MBA ’89
Founder and Chairman, Access Industries

The "Frontiers in Therapeutics" panel discussion will be moderated by Mark Namchuk and feature the following panelists:

Linda Avey
Co-Founder and Chief Executive Officer, Precisely, Inc.
 
Kevin Bitterman, PhD
Partner, Atlas Venture
 
Timothy A. Springer, PhD
Latham Family Professor of Medicine, Professor Pediatrics
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Program in Cellular and Molecular Medicine, Boston Children's Hospital
Co-Founder and Executive Chair, Institute for Protein Innovation


The I-Hub (Ideation Hub) at Harvard Medical School is a new initiative that aims to build community and catalyze ideation in therapeutics science, help faculty and students assemble interdisciplinary teams to prosecute translational projects, and provide early-stage support.

The Translator at Harvard Medical School is a new organization that is tasked with accelerating the movement of fundamental science at Harvard Medical School toward the medicines of tomorrow. The Translator works across a number of disease areas and therapeutic modalities via several translational research programs.

Press Contact

Caroline Perry
(617) 495-4157
Email